Tobira Therapeutics Inc. Announces Publication of Cenicriviroc Formulation Improvement Providing Platform for Single Tablet and Fixed-Dose Combinations
Published: Oct 04, 2013
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tobira Therapeutics today announced that the American Chemical Society’s journal Molecular Pharmaceutics published an article detailing the cenicriviroc (CVC) drug product formulation and process optimization. This article provides insight into formulation and process advancements, which represent significant breakthroughs in enabling once daily dosing with a single tablet in multiple indications, including the treatment of HIV. These data also establish the basis for future product pipeline diversification by allowing fixed-dose combinations in indications where conveniently administered single tablet multidrug combinations are the standard of care. Tobira’s lead product, cenicriviroc, is a novel oral, once daily, fixed-dose combinable, dual antagonist of chemokine receptors CCR2 and CCR5 being developed for the treatment of HIV-1 infection, graft versus host disease (GVHD), fibrosis and certain oncology indications in which CCR2 and CCR5 play a biological role.
Help employers find you! Check out all the jobs and post your resume.